Sagimet Biosciences SGMT 深 沪
等待开盘 11-04 09:30:00 美东时间
8.06
-0.460
-5.40%
华盛通- 最 高8.624
- 今 开8.48
- 成交量 38.82万股
- 最 低 8.03
- 昨 收 8.52
- 总市值 2.59亿
- 52周最高 11.41
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.73
- 委 比 3.96%
- 总股本 3219.53万
- 历史最高 20.71
- 量 比 0.73
- 振 幅 6.97%
- 历史最低 1.73
- 每 手 1
- 风险率 2.16%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Denifanstat Achieved All Endpoints in the Treatment of Moderate to Severe Acne in Phase 3 Clinical Trial in Acne in China: A Presentation at the 2025 Fall Clinical Dermatology Conference
Sagimet Biosciences announced that Denifanstat, an oral FASN inhibitor developed for treating moderate to severe acne, met all primary and secondary endpoints in a Phase 3 trial conducted by Ascletis in China. The trial, involving 480 patients, showed statistically significant improvements in acne severity and lesion reduction. Ascletis plans to submit an NDA to China's NMPA for Denifanstat shortly after completing pre-NDA consultations. Addition...
10-24 11:00
美股大行评级 | 超配！万事达、Visa、Block获多家机构首予评级；奈飞、德州仪器遭多家机构下调目标价
今日重点评级关注：Canaccord Genuity：维持ATAI Life Sciences"买入"评级，目标价从11美元升至14美元；麦格理：维持Cleanspark"跑赢大市"评级，目标价从20美元升至30美元
10-23 10:06
Sagimet Biosciences, Inc. Class A (SGMT) Receives a New Rating from Clear Street
In a report released yesterday, Kaveri Pohlman from Clear Street initiated cove...
10-22 16:59
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero
Viking Therapeutics (NASDAQ:VKTX) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed t...
10-09 23:33
Sagimet Biosciences Announces Upcoming Presentation at AASLD—The Liver Meeting® 2025
Sagimet Biosciences announced that analyses of the Phase 2b FASCINATE-2 study showing denifanstat's effectiveness in improving fibrosis in advanced fibrosis patients will be presented at the AASLD Liver Meeting 2025. Results demonstrate significant fibrosis improvement and biomarker benefits in patients, particularly those with advanced baseline fibrosis. Denifanstat, a fatty acid synthase inhibitor, is under development for metabolic dysfunction...
10-07 11:00
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
Canaccord Genuity Maintains Buy on Sagimet Biosciences, Maintains $28 Price Target
Canaccord Genuity analyst Edward Nash maintains Sagimet Biosciences (NASDAQ:SGMT) with a Buy and maintains $28 price target.
10-02 20:25
Sagimet Doses First Participants In Phase 1 Pharmacokinetic Trial Of Combination Of Oral Once-Daily FASN Inhibitor, Denifanstat, And THR-β Agonist, Resmetirom; Topline Data Expected In H1 2026
Dosing has successfully commenced with healthy volunteersPrimary endpoints for the Phase 1 trial include safety, tolerability, and pharmacokinetic (PK) profile of the combinationTopline data are anticipated in the first
10-01 19:17
Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
Sagimet Biosciences has initiated a Phase 1 trial combining denifanstat, a FASN inhibitor, with resmetirom, a THR-β agonist, targeting metabolic dysfunction-associated steatohepatitis (MASH). The trial aims to evaluate safety, tolerability, pharmacokinetics, and potential drug interactions. Topline data are expected in the first half of 2026, with plans to advance to Phase 2 if successful. The combination's synergistic effects were previously obs...
10-01 11:00
Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week
<p>Sagimet Biosciences Inc. will participate in a panel discussion at Fierce Biotech Week in Boston, October 7-9, 2025. Marie O’Farrell, Ph.D., Senior Vice President of Research and Development at Sagimet, will present on "How Biotechs are Leveraging Artificial Intelligence (AI)/Machine Learning (ML) to Drive Efficiency and ROI" on Thursday, October 9, 2025, at 11:15am ET. The panel will focus on the use of AI in drug development, particularly Sa...
09-24 11:00
